Nrf2 (C-Term) Polyclonal Antibody

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a basic leucine zipper transcription factor encoded by NFE2L2 in humans that regulates the cellular antioxidant response. It is a 605-amino acid protein comprised of seven highly conserved Nrf2-ECH (Neh) homology domains. Nrf2 contains a large central domain that recruits transcriptional co-activators, mediates heterodimerization with the transcription factor Maf, and can be phosphorylated by GSK3 or the ubiquitin ligase adapter protein β-TrCP. The Nrf2 central domain is flanked by an N-terminal Neh2 domain that binds the negative regulator Kelch-like ECH-associated protein 1 (Keap1; ) and a C-terminal Neh3 domain that is required for transactivation. Nrf2 is ubiquitously expressed and, under homeostatic conditions, associates with Keap1 in the cytoplasm, preventing Nrf2 nuclear translocation and promoting its ubiquitination and proteasomal degradation. In the presence of xenobiotic electrophiles or oxidants, Keap1 releases Nrf2 which translocates to the nucleus, dimerizes with Maf, and induces the expression of a variety of cytoprotective genes that have antioxidant, anti-inflammatory, and metabolic functions. Nrf2 siRNA knockdown increases DNA-crosslinking and apoptosis induced by cisplatin in A549 cancer cells, indicating that Nrf2 contributes to chemoresistance. Tumor Nrf2 levels are increased in patients with non-small cell lung cancer (NSCLC) and this increase is associated with poor overall survival. Cayman''s Nrf2 (C-Term) Polyclonal Antibody can be used for flow cytometry (FC), immunocytochemistry (ICC), immunofluorescence (IF), and Western blot (WB) applications. The antibody preferentially recognizes polyubiquitinated Nrf2 at 90 kDa from human, mouse, and rat samples.

[1] MONTSERRAT ROJO DE LA VEGA D D Z Eli Chapman. NRF2 and the Hallmarks of Cancer.[J]. Journal of Proteome Research, 2018: 21-43. DOI: 10.1016/j.ccell.2018.03.022
[2] N. ROBLEDINOS-ANTóN. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development[J]. Oxidative Medicine and Cellular Longevity, 2019, 75 1. DOI: 10.1155/2019/9372182
[3] PETER CANNING  Alex N B  Fiona J Sorrell. Structural basis of Keap1 interactions with Nrf2[J]. Free Radical Biology and Medicine, 2015, 88: Pages 101-107. DOI: 10.1016/j.freeradbiomed.2015.05.034
[4] YU CHEN. Kinetic Analyses of Keap1–Nrf2 Interaction and Determination of the Minimal Nrf2 Peptide Sequence Required for Keap1 Binding Using Surface Plasmon Resonance[J]. Chemical Biology & Drug Design, 2011, 78 6: 1014-1021. DOI: 10.1111/j.1747-0285.2011.01240.x
[5] TAKAFUMI SUZUKI  Masayuki Y. Molecular basis of the Keap1–Nrf2 system[J]. Free Radical Biology and Medicine, 2015, 88: Pages 93-100. DOI: 10.1016/j.freeradbiomed.2015.06.006
[6] CLAUDIA TONELLI  David A T  Iok In Christine Chio. Transcriptional Regulation by Nrf2.[J]. Antioxidants & redox signaling, 2018, 29 17: 1727-1745. DOI: 10.1089/ars.2017.7342
[7] MOON-IL KANG. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101 7: 2046-2051. DOI: 10.1073/pnas.0308347100
[8] SHINSUKE HOMMA. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.[J]. Clinical Cancer Research, 2009: 3423-3432. DOI: 10.1158/1078-0432.ccr-08-2822
[9] LUISA M SOLIS. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.[J]. Clinical Cancer Research, 2010: 3743-3753. DOI: 10.1158/1078-0432.ccr-09-3352